Franz Xaver Schwarz

USPTO Granted Patents = 12 (Patent Applications = 8)

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 13)

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Woergl, AT (2012)
Wörgl, AT (2010 - 2014)
Worgl, AT (2010 - 2017)
Kundl, AT (2015 - 2020)
Kundl/Tirol, AT (2021)

Company Filing History:

Years Active: 2010-2021

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11052071 - Oral dosage form comprising rifaximin in form beta (2021-07-06),

2. 10842782 - Storage stable composition comprising rifaximin alpha (2020-11-24),

3. 9867829 - Stable pharmaceutical composition containing 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof (2018-01-16),

4. 9629810 - Capsule with soluble blocking element (2017-04-25),

5. 9566337 - Powder mixtures for antibiotic dry syrup formulations (2017-02-14),

6. 9375108 - Device for the oral application of a substance (2016-06-28),

7. 9227938 - Pharmaceutical composition containing crystalline sorafenib tosylate (2016-01-05),

8. 9198833 - Method and device for oral application of a composition (2015-12-01),

9. 8715734 - Amoxicilline instant granulate (2014-05-06),

10. 8168228 - Antibiotic clarithromycin micropellet compositions (2012-05-01),

11. 7807196 - Process for drying amoxicillin (2010-10-05),

12. 7767231 - Taste-masking pharmaceutical compositions (2010-08-03),

Title: Franz Xaver Schwarz: Innovator in Pharmaceutical Formulations

Introduction

Franz Xaver Schwarz is a notable inventor based in Kundl, Austria. He has made significant contributions to the field of pharmaceuticals, particularly in the development of oral dosage forms. With a total of 12 patents to his name, his work has had a considerable impact on drug delivery systems.

Latest Patents

Among his latest innovations is a patent for an oral dosage form comprising rifaximin in the beta form. This invention focuses on providing a delayed release of the active pharmaceutical agent, enhancing the effectiveness of the treatment. Another significant patent is for a storage-stable composition containing rifaximin alpha. This pharmaceutical composition utilizes a stable polymorph of rifaximin along with a wicking agent, showcasing his expertise in creating effective and reliable drug formulations.

Career Highlights

Franz Xaver Schwarz has worked with prominent companies in the pharmaceutical industry, including Sandoz AG and Sandoz GmbH. His experience in these organizations has allowed him to refine his skills and contribute to various innovative projects.

Collaborations

Throughout his career, he has collaborated with talented individuals such as Stefan Scheler and Johannes Raneburger. These partnerships have fostered a creative environment that has led to the development of groundbreaking pharmaceutical solutions.

Conclusion

Franz Xaver Schwarz stands out as a key figure in the pharmaceutical industry, with a strong portfolio of patents that reflect his innovative spirit. His contributions continue to influence the field of drug delivery and formulation.

This text is generated by artificial intelligence and may not be accurate.